Genomenon, Inc

We are proud to celebrate our CEO, Mike Klein, recognized as Entrepreneur of the Year by the Michigan Venture Capital Association (MVCA), for his visionary leadership and relentless drive that continue to propel Genomenon forward in transforming the landscape of genomic research and making genomic information actionable. Congratulations Mike! 🎉

Did you know? The TP53 gene, often called the “guardian of the genome,” is essential for protecting our cells from becoming cancerous. It encodes the p53 protein, which plays a critical role in regulating the cell cycle, repairing DNA damage, and initiating apoptosis (programmed cell death) when necessary. This means that TP53 acts as a crucial checkpoint in preventing tumor formation. However, variants in the TP53 gene are among the most common alterations found in various cancers, including breast, lung, and colon cancers. These variants can lead to a loss of its tumor-suppressing abilities, allowing cancer cells to proliferate unchecked. Research on TP53 continues to be pivotal in the fight against cancer, making it a vital area of focus for scientists and healthcare professionals alike. 🔍 In Mastermind, there are 50.4K classified variants available for this gene:  https://lnkd.in/gBdTBH_A #TP53 #CancerResearch #Genetics #Genomics #TumorSuppression #PersonalizedMedicine #HealthcareInnovation #Genomenon #MastermindGIP

Attending #ICoNS2024? Connect with members of the Genomenon leadership team today at the International Consortium on Newborn Sequencing in New York! Meet with our CEO Mike Klein, COO Samuel Globus, PhD, VP of Marketing Colleen McMillen, and Founder and CSO, Mark J. Kiel MD PhD (not pictured) to learn about our mission to curate the human genome and how that will unleash the power of every genome with a thorough understanding of variant pathogenicity - and will also empower the development of precision medicines targeted at rare diseases.

Each month, we highlight a gene you can find curated on the Mastermind® Genomic Intelligence Platform. For October, we are featuring THBD! This gene encodes thrombomodulin, a crucial protein involved in regulating blood coagulation. Variants in THBD can lead to issues with clot formation and are associated with an increased risk of thrombosis, which has serious clinical implications, including venous thromboembolism and other blood clotting disorders. To support the research community, we have curated 26,000+ articles on THBD, establishing a comprehensive resource on its role in thrombosis and related conditions. This collection includes cutting-edge research, clinical data, and detailed variant insights. This curated content is available to all Mastermind users. Whether you’re a researcher delving into the intricacies of THBD or a clinician looking for the latest developments, our platform gives you access to an extensive collection of variant data and clinical insights. 🧬 Create a free Mastermind account to explore the platform this invaluable resource and gain a deeper understanding of THBD: https://lnkd.in/g7c_Fzs #THBD #Thrombosis #Genetics #Genomics #Genomenon #MastermindGIP #GeneticResearch #ClinicalResearch

In our latest blog, we dive into the critical importance of global health initiatives and how genomics is paving the way for more personalized and equitable healthcare solutions. From addressing genetic disorders to driving cutting-edge research, these initiatives are making a worldwide impact—and Genomenon is proud to be part of the effort. To mark Healthy Lung Month, we’re offering free access to curated variant insights on genes associated with pulmonary diseases, including KCNK3, TET2, SERPINA1, RTEL1, ODAD3, ODAD2, ENG, and CFTR. These insights are available through our Mastermind® Genomic Intelligence Platform, empowering researchers to make breakthroughs in understanding and treating respiratory conditions. 🔗 Read the full blog: https://lnkd.in/gacabMub 🧬 Sign up for a Mastermind account and unlock valuable variant insights without any cost: https://lnkd.in/g7c_Fzs #GenomicResearch #GlobalHealth #BlogPost #PulmonaryDiseases #MastermindGIP #raredisease #GeneAccess #HealthyLungMonth #Genomenon

Did you know that your ability to handle cold isn’t just about bundling up—it’s in your genes too! One gene, UCP1, plays a major role in how your body generates heat by activating brown fat, a special type of fat that burns energy to produce heat. When temperatures drop, the UCP1 protein helps your body convert fat into warmth, making a big difference in how you tolerate the cold! 🧊🔥 While there are other factors like environment and behavior, UCP1 is a key player in your body’s cold response! 🔍 Learn more about UCP1 gene on Mastermind: https://lnkd.in/gts4j7qZ

Latest News: Genomenon has released curated evidence of all the ACMG secondary findings in the Mastermind® Genomic Intelligence Platform! As the number of labs analyzing whole genome and whole exome tests rises, more variants appear on tests that may be outside the initial focus for the health care provider and patient. Variants in these genes can predispose individuals to severe medical conditions, often without initial symptoms. Reporting these findings is highly recommended by ACMG and can be crucial for patients. The curated data for ACMG secondary findings is available in the Mastermind Professional Edition today. 👉 Read the full announcement here: https://lnkd.in/gMyXcqty 💬 Learn from Genomenon's founder and CSO Mark J. Kiel MD PhD and Director of Product Quality Anna McGill, in our latest video about the impact of these findings here: https://lnkd.in/gZ5BG2Pu 🧬 Login to Mastermind and explore! Don't have a Mastermind login, join for free! https://lnkd.in/g7c_Fzs

At Genomenon, we are deeply committed to advancing the research and care that directly impacts those living with genetic diseases including pulmonary disorders. This Healthy Lung Month, we are offering free access to curated variant content on a subset of genes known to impact pulmonary diseases and related phenotypes from our Mastermind® Genomic Intelligence Platform. The variant insights provided are from the genes KCNK3, TET2, SERPINA1, RTEL1, ODAD3, ODAD2, ENG and CFTR. Our goal is to support the research community by making vital genomic data more accessible, providing a foundation for new insights and breakthroughs. The variant content will be available for all Mastermind users, and anyone can create a free Mastermind account here: https://lnkd.in/gzirC_3E We are committed to supporting your research and hope this resource proves valuable as you continue to explore and innovate in the field. #HealthyLungMonth #Genetics #PulmonaryDisorders #Genomics #DiseaseAwareness #ClinicalResearch #Genomenon #MastermindGIP

Michigan Tech Week is where high-growth entrepreneurs, investors, & leaders from both peninsulas connect, collaborate & innovate! Genomenon's CEO, Mike Klein, will be a panelist at Thursday's discussion on 'Saving Hearts & Lives, One Start-Up At A Time', where he'll share his insights & experience as a serial entrepreneur and tech leader! 🚀 #MITechWeek #InnovateMichigan

As we continue to feature our remarkable genomic scientists, we’re happy to introduce Amna Kumašin! Amna, a Variant Curation Scientist I at Genomenon, holds a Bachelor of Science in Genetics and Bioengineering from the International University of Sarajevo (IUS) and a Master of Science in Bioengineering Innovations in Precision Medicine, a joint degree awarded by Université Grenible Alpes, Universitat de Barcelona, and Università degli Studi di Napoli Federico II. Amna’s passion for genomics stems from her background in genetics and bioengineering, combined with her experience in precision medicine, which revealed to her the transformative potential of genomic technologies in personalized healthcare. She joined Genomenon because of “[...] its commitment to advancing genomic science and its culture that fosters growth and innovation.” Amna also noted that she “loves working at Genomenon because it provides a collaborative and supportive environment that helps me expand my knowledge and enhance my attention to detail” and that it “[...] enables me to accurately analyze complex genetic variants and make informed contributions to research and diagnostics.” She also explained that her favorite part of her job is “[...] analyzing complex genomic data to uncover insights that drive advancements in research and improve diagnostic accuracy” and that this is especially important because “[...] accurate variant interpretation and classification are crucial for identifying disease-associated mutations and guiding effective treatment strategies.” In particular, Amna identified BRCA2 and THRB as being of interest to her due to the complexity of their variants. She also shared that she thinks a common misunderstanding is that genomics “[...] only involves sequencing DNA, whereas it also encompasses the complex analysis and interpretation of genetic data to understand its implications for health and disease.”